Cardiovascular Drugs and Therapy

, Volume 3, Issue 5, pp 675–682 | Cite as

Inhibition of calmodulin and protein kinase C by amiodarone and other class III antiarrhythmic agents

  • Paul J. Silver
  • Mary J. Connell
  • Kathleen M. Dillon
  • Wayne R. Cumiskey
  • Walter A. Volberg
  • Alan M. Ezrin
Antiarrhythmic Agents

Summary

Class III antiarrhythmic agents may prolong refractoriness via modulation of ion channels, which may be sensitive to Ca2+ regulatory proteins or enzymes. Accordingly, the purpose of this study was to quantitate the effects of several structurally diverse class III antiarrhythmic agents on calmodulin-regulated enzymes and protein kinase C activity, and to evaluate the ability of these agents and known calmodulin antagonists to prolong cardiac refractoriness in vivo. The rank order of potency (IC50;μM) of selected class III antiarrhythmic agents and reference calmodulin antagonists as inhibitors of calmodulin-regulated phosphodiesterase activity were: calmidazolium (0.12 μM)>amiodarone (0.62 μM)>desethylamiodarone (1.5 μM)>trifluoperazine (4.3 μM), bepridil (5 μM)>W-7 (7.5 μM), clofilium (13 μM). Similar concentration-related inhibition was evident in a second calmodulin-regulated system, inhibition of myosin light-chain phosphorylation and superprecipitation light-chain phosphorylation and superprecipitation of arterial actomyosin. Sotalol and tetraethylammonium were inactive at 100 μM. Protein kinase C activity was also inhibited by some of these agents; desethylamiodarone (IC50=11 μM) was more potent than the reference agent, H-7 (IC50=79 μM), or amiodarone (38% inhibition at 100 μM) and clofilium (32% inhibition at 100 μM). In vivo, the minimally effective doses required to increase ventricular effective refractory doses required to increase ventricular effective refractory periods in paced guinea pigs were (in mg/kg) bepridil, sotalol [1]>clofilium [3]>amiodarone [10]>W-7, desethylamiodarone [20]. No changes in refractory period were noted with maximum testable doses of calmidazolium or trifluoperazine. These studies show that some, but not all, class III antiarrhythmic agents are effective and potent calmodulin antagonists or protein kinase C inhibitors. Moreover, some calmodulin antagonists are effective at prolonging refractoriness in vivo. However, a lack of correlation between these agents suggests that these mechanisms are not solely responsible for the prolongation of refractoriness of all class III agents.

Key Words

calmodulin protein kinase C antiarrhythmic drugs 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kikkawa U, Nishizuka Y. Protein kinase C.The Enzymes 1986;17:167–189.Google Scholar
  2. 2.
    Rasmussen H, Takuwa Y, Park S. Protein kinase C in the regulation of smooth muscle contraction.FASEB J 1987;1:177–185.PubMedGoogle Scholar
  3. 3.
    Roufogalis BD. Calmodulin antagonism. In: Marme D (ed).Calcium and Cell Physiology. Berlin: Springer-Verlag, 1985:148–168.Google Scholar
  4. 4.
    Silver PJ. Pharmacological modulation of cardiac and vascular contractile protein function.J Cardiovasc Pharmacol 1986;8 (Suppl 9):S34-S46.Google Scholar
  5. 5.
    Levitan IB. Phosphorylation of ion channels.J Membrane Biol 1985;87:177–190.Google Scholar
  6. 6.
    Luchowski EM, Youssif F, Triggle DJ, et al. Effects of metal cations and calmodulin antagonists on3H-nitrendipine binding in smooth and cardiac muscle.J Pharmacol Exp Ther 1984;230:607–613.PubMedGoogle Scholar
  7. 7.
    Lackington I, Orrego F. Inhibition of calcium-activated potassium conductance of human erythrocytes by calmodulin inhibitory drugs.FEBS Lett 1981;133:103–106.PubMedGoogle Scholar
  8. 8.
    Vaughn-Williams EM. A classification of antiarrhythmic actions re-assessed after a decade of new drugs.J Clin Pharmacol 1984;24:129–147.PubMedGoogle Scholar
  9. 9.
    Cohen IS, Datyner NB, Gintant GA, et al. Time dependent outward currents in the heart. In: Fozzard HA, et al. (eds).The Heart and Cardiovascular System. New York: Raven Press, 1986:637–669.Google Scholar
  10. 10.
    Weishaar RE, Burrows JD, Kobylarz DC, et al. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets: Isolation, characterization and effects on various reference phosphodiesterase inhibitors and cardiotonic agents.Biochem Pharmacol 1986;35:787–800.PubMedGoogle Scholar
  11. 11.
    Silver PJ, Hamel LT, Perrone MH, et al. Differential pharmacological sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle.Eur J Pharmacol 1988;150:85–94.PubMedGoogle Scholar
  12. 12.
    Norman JA, Ansell J, Stone GA, et al. CGS9343B, a novel, potent and selective inhibitor of calmodulin activity.Mol Pharmacol 1987;31:535–540.PubMedGoogle Scholar
  13. 13.
    Tallarida RJ, Murray RB (eds).Manual of Pharmacologic Calculations with Computer Programs, 2nd ed. New York: Springer-Verlag, 1986.Google Scholar
  14. 14.
    Silver PJ, Dachiw J, Ambrose JM. Effects of calcium antagonists and vasodilators on arterial myosin phosphorylation and actin-myosin interactions.J Pharmacol Exp Ther 1984;230:141–148.PubMedGoogle Scholar
  15. 15.
    Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.Anal Biochem 1976;72:248–254.PubMedGoogle Scholar
  16. 16.
    Jeng AY, Sharkley NA, Blumberg PM. Purification of stable protein kinase C from mouse brain cytosol by specific ligand elution using fast protein liquid chromatography.Cancer Res 1986;46:1966–1971.PubMedGoogle Scholar
  17. 17.
    Corbin JD, Reimann EM. Assay of cyclic AMP-dependent protein kinases.Methods Enzymol 1974;38:287–290.PubMedGoogle Scholar
  18. 18.
    Holt G, Tucker G, Jackson P, et al. Amiodarone pharmacokinetics.Am Heart J 1983;106:840–847.PubMedGoogle Scholar
  19. 19.
    Lamers JMJ, Cysouw KJ, Verdouw PD. Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase.Biochem Pharmacol 1985;34:3837–3843.PubMedGoogle Scholar
  20. 20.
    Zimmer M, Hofmann F. Calmodulin antagonists inhibit activity of myosin light-chain kinase independent of calmodulin.Eur J Biochem 1984;142:393–397.PubMedGoogle Scholar
  21. 21.
    Mazzei GJ, Schatzman RC, Turner RS, et al. Phospholipid-sensitive Ca2+-dependent protein kinase inhibition by R-24571, a calmodulin antagonist.Biochem Pharmacol 1984;33:125–130.PubMedGoogle Scholar
  22. 22.
    Tanaka T, Okmura T, Yamakado T, et al. Two types of calcium-dependent protein phosphorylations modulated by calmodulin antagonists.Mol Pharmacol 1982;22:408–412.PubMedGoogle Scholar
  23. 23.
    Kuo CS, Reddy CP, Munakata K, et al. Arrhythmias dependent predominantly on dispersion or repolarization. In: Zipes DP, Jalife J (eds).Cardiac Electrophysiology Arrhythmias. New York: Grune and Stratton, 1985:277–286.Google Scholar
  24. 24.
    DiFrancesco D, McNaughton PA. The effects of calcium on outward membrane current in the cardiac Purkinje fibre.J Physiol (Lond) 1979;289:347–373.Google Scholar
  25. 25.
    Kass RS. Delayed rectification in the cardiac Purkinje fiber is not activated by intracellular calcium.Biophys J 1984;45:837–839.PubMedGoogle Scholar
  26. 26.
    Bkaily G, Sperelakis N, Eldefrawi M. Effects of the calmodulin inhibitor, trifluoperazine, on membrane potentials and slow action potentials of cultured heart cells.Eur J Pharmacol 1984;105:23–31.PubMedGoogle Scholar
  27. 27.
    Barron E, Marshall RJ, Martorana M, et al. Comparative antiarrhythmic and electrophysiological effects of drugs known to inhibit calmodulin (TFP, W-7 and bepridil).Br J Pharmacol 1986;89:603–612.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • Paul J. Silver
    • 1
  • Mary J. Connell
    • 1
  • Kathleen M. Dillon
    • 1
  • Wayne R. Cumiskey
    • 1
  • Walter A. Volberg
    • 1
  • Alan M. Ezrin
    • 1
  1. 1.Department of PharmacologySterling-Winthrop Research InstituteRensselaerUSA

Personalised recommendations